S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NYSE:EQH

Equitable Stock Competitors

$33.32
-0.98 (-2.86%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$33.22
$34.27
50-Day Range
$30.59
$35.98
52-Week Range
$24.56
$36.33
Volume
4.43 million shs
Average Volume
2.88 million shs
Market Capitalization
$13.49 billion
P/E Ratio
3.15
Dividend Yield
2.10%
Beta
1.65

Equitable (NYSE:EQH) Vs. AJG, WLTW, WTW, BRO, WDH, RYAN, GSHD, BRP, BRP, and CRVL

Should you be buying Equitable stock or one of its competitors? The main competitors of Equitable include Arthur J. Gallagher & Co. (AJG), Willis Towers Watson Public (WLTW), Willis Towers Watson Public (WTW), Brown & Brown (BRO), Waterdrop (WDH), Ryan Specialty Group (RYAN), Goosehead Insurance (GSHD), BRP Group (BRP), BRP Group (BRP), and CorVel (CRVL). These companies are all part of the "insurance agents, brokers, & service" industry.

Equitable vs.

Willis Towers Watson Public (NASDAQ:WLTW) and Equitable (NYSE:EQH) are both large-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment.

89.3% of Willis Towers Watson Public shares are owned by institutional investors. Comparatively, 92.4% of Equitable shares are owned by institutional investors. 0.9% of Willis Towers Watson Public shares are owned by company insiders. Comparatively, 0.2% of Equitable shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Willis Towers Watson Public has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Equitable has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.

Willis Towers Watson Public currently has a consensus price target of $247.91, indicating a potential upside of ∞. Equitable has a consensus price target of $44.22, indicating a potential upside of 32.72%. Given Willis Towers Watson Public's higher possible upside, equities analysts clearly believe Willis Towers Watson Public is more favorable than Equitable.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Willis Towers Watson Public
0 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.55
Equitable
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

Willis Towers Watson Public has a net margin of 23.88% compared to Equitable's net margin of 0.00%. Willis Towers Watson Public's return on equity of 15.12% beat Equitable's return on equity.

Company Net Margins Return on Equity Return on Assets
Willis Towers Watson Public 23.88% 15.12% 4.52%
Equitable N/A N/A N/A

Willis Towers Watson Public pays an annual dividend of $3.20 per share. Equitable pays an annual dividend of $0.72 per share and has a dividend yield of 2.2%. Willis Towers Watson Public pays out 18.1% of its earnings in the form of a dividend. Equitable pays out 6.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Willis Towers Watson Public has increased its dividend for 6 consecutive years and Equitable has increased its dividend for 3 consecutive years. Equitable is clearly the better dividend stock, given its higher yield and lower payout ratio.

Willis Towers Watson Public received 339 more outperform votes than Equitable when rated by MarketBeat users. Likewise, 63.68% of users gave Willis Towers Watson Public an outperform vote while only 62.06% of users gave Equitable an outperform vote.

CompanyUnderperformOutperform
Willis Towers Watson PublicOutperform Votes
568
63.68%
Underperform Votes
324
36.32%
EquitableOutperform Votes
229
62.06%
Underperform Votes
140
37.94%

Equitable has higher revenue and earnings than Willis Towers Watson Public. Willis Towers Watson Public is trading at a lower price-to-earnings ratio than Equitable, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Willis Towers Watson Public$9.35 billion0.00$996 million$17.69N/A
Equitable$12.42 billion1.09$4.28 billion$10.583.15

In the previous week, Equitable had 6 more articles in the media than Willis Towers Watson Public. MarketBeat recorded 6 mentions for Equitable and 0 mentions for Willis Towers Watson Public. Willis Towers Watson Public's average media sentiment score of 1.27 beat Equitable's score of 0.39 indicating that Willis Towers Watson Public is being referred to more favorably in the media.

Company Overall Sentiment
Willis Towers Watson Public Positive
Equitable Neutral

Summary

Willis Towers Watson Public beats Equitable on 11 of the 20 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EQH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Equitable (NYSE:EQH) vs. Its Competitors

TypeEquitableInsurance agents, brokers, & service IndustryFinance SectorNYSE Exchange
Market Cap$13.49B$16.19B$8.44B$14.86B
Dividend Yield2.10%2.96%5.40%3.54%
P/E Ratio3.1527.7612.5121.45
Price / Sales1.096.55110.7622.40
Price / CashN/A36.6130.8483.01
Price / BookN/A4.602.8811.40
Net IncomeN/A$809.80M$629.30M$426.90M
7 Day Performance-7.39%-4.74%-3.31%-5.49%
1 Month Performance2.40%-9.33%110.31%-4.46%
1 Year Performance23.77%-13.75%134.73%8.81%

Equitable Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AJG
Arthur J. Gallagher & Co.
2.8598 of 5 stars
$154.17
-1.0%
$169.52
-10.0%
+29.5%$31.96B$7.00B33.3732,401Upcoming Earnings
WLTW
Willis Towers Watson Public
2.9243 of 5 stars
N/A$247.91
-∞
N/A$28.85B$9.35B13.0946,100Positive News
WTW
Willis Towers Watson Public
1.0833 of 5 stars
$225.64
-1.2%
N/AN/A$28.12B$9.35B12.7646,100Analyst Downgrade
News Coverage
BRO
Brown & Brown
2.2756 of 5 stars
$63.13
-1.8%
$66.75
-5.7%
+33.0%$17.83B$2.61B30.805,764Upcoming Earnings
Dividend Announcement
WDH
Waterdrop
1.825 of 5 stars
$1.28
-7.8%
$11.43
-793.2%
N/A$5.04B$464.05M0.004,291
RYAN
Ryan Specialty Group
1.532 of 5 stars
$36.88
-1.3%
$36.88
-0.0%
N/A$4.05B$1.02B0.001,214Lockup Expiration
News Coverage
GSHD
Goosehead Insurance
2.7043 of 5 stars
$92.50
-0.5%
$160.00
-73.0%
-34.4%$3.42B$117.01M243.43946
BRP
BRP Group
2.875 of 5 stars
$28.76
-1.7%
$39.20
-36.3%
+6.8%$3.23B$137.84M-41.681,494Analyst Downgrade
News Coverage
BRP
BRP Group
2.7514 of 5 stars
$28.76
-1.7%
$39.20
-36.3%
+6.8%$3.23B$240.92M-61.191,524Short Interest ↑
CRVL
CorVel
1.5464 of 5 stars
$177.67
-0.1%
N/A+71.2%$3.15B$552.64M54.843,681
SLQT
SelectQuote
2.1315 of 5 stars
$7.39
-4.2%
$21.25
-187.6%
-70.4%$1.21B$937.82M14.491,356Analyst Downgrade
GOCO
GoHealth
2.8589 of 5 stars
$2.49
-6.8%
$8.71
-250.0%
-83.6%$798.56M$877.35M27.673,067Gap Down
EHTH
eHealth
2.6264 of 5 stars
$22.14
-5.1%
$39.22
-77.2%
-72.8%$584.23M$582.77M-23.811,960Analyst Downgrade
News Coverage
FANH
Fanhua
2.0915 of 5 stars
$6.75
-1.9%
N/A-51.5%$362.44M$500.86M8.234,926
ADF
Aldel Financial
0 of 5 stars
$14.55
-3.0%
N/AN/A$217.49MN/A0.002News Coverage
HGTY
Hagerty
0 of 5 stars
$14.55
-3.0%
N/AN/A$217.49MN/A0.002
HUIZ
Huize
0.8448 of 5 stars
$1.19
-10.9%
N/A-81.9%$61.83M$187.01M-2.531,314News Coverage
TIRX
Tian Ruixiang
0 of 5 stars
$1.23
-3.3%
N/AN/A$9.84M$3.25M0.0044Short Interest ↑
This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.